Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854426 | 1.00 | PLA2G2A (0.49) | PLA2G2AHDAC1HDAC6GFERPPARG | |
| SCHEMBL3853782 | 0.90 | PLA2G2A (0.53) | PLA2G2AHDAC1HDAC6GFERPPARG | |
| SCHEMBL3853784 | 0.90 | PLA2G2A (0.53) | PLA2G2AHDAC1HDAC6GFERPPARG | |
| SCHEMBL3855369 | 0.89 | PLA2G2A (0.51) | PLA2G2AHDAC1HDAC6GFERPTGDR2 | |
| SCHEMBL3855368 | 0.89 | PLA2G2A (0.51) | PLA2G2AHDAC1HDAC6GFERPTGDR2 | |
| SCHEMBL3858100 | 0.89 | ADAM17 (0.56) | PLA2G2AGFERPPARGPTGDR2ADAM17 | |
| SCHEMBL3858097 | 0.89 | ADAM17 (0.56) | PLA2G2AGFERPPARGPTGDR2ADAM17 | |
| SCHEMBL3858120 | 0.85 | ADAM17 (0.44) | PLA2G2AGFERPPARGADAM17 | |
| SCHEMBL3858116 | 0.85 | ADAM17 (0.44) | PLA2G2AGFERPPARGADAM17 | |
| SCHEMBL3849889 | 0.83 | PPARG (0.53) | PLA2G2APPARGADAM17PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576222-B2 | N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | ADAM17, TPSAB1, ADAM10 | PLA2G2A 3197/4885HDAC1 589/4885HDAC6 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.